Tag : APL

  • NEWS AND PERSPECTIVE
    HKUMed’s revolutionary oral arsenic trioxide for APL secures FDA & EMA designation

    Acute promyelocytic leukemia (APL) is a rapidly fatal disease without timely treatment. A recent breakthrough from the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) is changing the global treatment landscape of APL with the development of an oral formulation of arsenic trioxide (oral-ATO). Backed by over 20 years of clinical data, oral-ATO has now received orphan drug designation (ODD) from both the United States (US) Food and Drug Administration (FDA) and European Medicines Agency (EMA). Led by Dr. Singh, Gill Harinder Harry, Clinical Associate Professor at HKUMed, the team is pioneering a new era in APL treatment, bringing this life-saving innovation from Hong Kong to the global stage.

    doctor name

    Dr. Singh Gill Harinder Harry

    Clinical Assistant Professor, Department of Medicine, The University of Hong Kong